Full-dose versus half-dose systemic thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: 30-day mortality and its determinants in a 10-year real-world cohort

Background Systemic thrombolysis is recommended for high-risk pulmonary embolism (PE) and may be considered in selected patients with intermediate-high-risk PE. However, factors associated with short-term mortality among patients receiving thrombolytic therapy and the clinical impact of reduced-dose regimens remain incompletely defined. Methods This retrospective single-center cohort included 115 consecutive adults with acute high-risk or intermediate-high-risk PE who received systemic thrombolytic therapy between January 2013 and December 2022. Patients were categorized as receiving full-dose thrombolysis (alteplase 100 mg or standard-dose reteplase) or half-dose thrombolysis (alteplase 50 mg). The primary outcome was 30-day all-cause mortality. Factors associated with mortality were evaluated using conventional logistic regression. Because of the limited number of outcome events and complete separation for supplemental oxygen requirement, Firth penalized logistic regression was additionally performed as a sensitivity analysis. Results Thirty-day mortality occurred in 29 patients (25.2%); rates were 23.3% in the full-dose group and 28.6% in the half-dose group (OR 1.31, 95% CI 0.50–3.38; p = 0.656). In the primary multivariable model, CRP (adjusted odds ratio [aOR] 1.095 per 10 mg/L, 95% CI 1.015–1.180; p = 0.019) and hemodynamic instability (aOR 4.642, 95% CI 1.397–15.423; p = 0.012) were independently associated with 30-day mortality, whereas thrombolytic treatment strategy was not (aOR 1.442, 95% CI 0.428–4.857; p = 0.555). These findings were preserved in a six-covariate Firth model. When supplemental oxygen requirement was additionally incorporated into the penalized model, hemodynamic instability remained significantly associated with mortality (aOR 3.783, 95% CI 1.208–12.487; p = 0.022), whereas the association with CRP was attenuated (aOR 1.066 per 10 mg/L, 95% CI 0.996–1.148; p = 0.067). All 30-day deaths occurred among patients requiring supplemental oxygen (Fisher’s exact p < 0.001). Conclusions Hemodynamic instability showed the most robust association with 30-day mortality among thrombolysis-treated patients with acute high-risk and intermediate-high-risk PE. CRP demonstrated a prognostic association that was sensitive to model specification, whereas thrombolytic treatment strategy was not independently associated with mortality. These findings emphasize the prognostic importance of acute hemodynamic and respiratory compromise and warrant validation in larger prospective multicenter cohorts.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11515049/v1
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Full-dose versus half-dose systemic thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: 30-day mortality and its determinants in a 10-year real-world cohort

Bülent Altınsoy, Müge Meltem Tor, Ayşegül TOMRUK ERDEM, Gizem Karakurt
2 links
Research Square
Venous Thromboembolism Diagnosis and Management
preprint

Full-dose versus half-dose systemic thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: 30-day mortality and its determinants in a 10-year real-world cohort

Bülent Altınsoy, Müge Meltem Tor, Ayşegül TOMRUK ERDEM, Gizem Karakurt
preprint en

Abstract

Background Systemic thrombolysis is recommended for high-risk pulmonary embolism (PE) and may be considered in selected patients with intermediate-high-risk PE. However, factors associated with short-term mortality among patients receiving thrombolytic therapy and the clinical impact of reduced-dose regimens remain incompletely defined. Methods This retrospective single-center cohort included 115 consecutive adults with acute high-risk or intermediate-high-risk PE who received systemic thrombolytic therapy between January 2013 and December 2022. Patients were categorized as receiving full-dose thrombolysis (alteplase 100 mg or standard-dose reteplase) or half-dose thrombolysis (alteplase 50 mg). The primary outcome was 30-day all-cause mortality. Factors associated with mortality were evaluated using conventional logistic regression. Because of the limited number of outcome events and complete separation for supplemental oxygen requirement, Firth penalized logistic regression was additionally performed as a sensitivity analysis. Results Thirty-day mortality occurred in 29 patients (25.2%); rates were 23.3% in the full-dose group and 28.6% in the half-dose group (OR 1.31, 95% CI 0.50–3.38; p = 0.656). In the primary multivariable model, CRP (adjusted odds ratio [aOR] 1.095 per 10 mg/L, 95% CI 1.015–1.180; p = 0.019) and hemodynamic instability (aOR 4.642, 95% CI 1.397–15.423; p = 0.012) were independently associated with 30-day mortality, whereas thrombolytic treatment strategy was not (aOR 1.442, 95% CI 0.428–4.857; p = 0.555). These findings were preserved in a six-covariate Firth model. When supplemental oxygen requirement was additionally incorporated into the penalized model, hemodynamic instability remained significantly associated with mortality (aOR 3.783, 95% CI 1.208–12.487; p = 0.022), whereas the association with CRP was attenuated (aOR 1.066 per 10 mg/L, 95% CI 0.996–1.148; p = 0.067). All 30-day deaths occurred among patients requiring supplemental oxygen (Fisher’s exact p < 0.001). Conclusions Hemodynamic instability showed the most robust association with 30-day mortality among thrombolysis-treated patients with acute high-risk and intermediate-high-risk PE. CRP demonstrated a prognostic association that was sensitive to model specification, whereas thrombolytic treatment strategy was not independently associated with mortality. These findings emphasize the prognostic importance of acute hemodynamic and respiratory compromise and warrant validation in larger prospective multicenter cohorts.

Research Square
Ministry of Health (TR), Zonguldak Bülent Ecevit University (TR)
Good health and well-being
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon